PL2247282T3 - Preparat o przedłużonym uwalnianiu zawierający oktreotyd oraz trzy liniowe kopolimery poli(laktyd-co-glikolid) - Google Patents

Preparat o przedłużonym uwalnianiu zawierający oktreotyd oraz trzy liniowe kopolimery poli(laktyd-co-glikolid)

Info

Publication number
PL2247282T3
PL2247282T3 PL09705454T PL09705454T PL2247282T3 PL 2247282 T3 PL2247282 T3 PL 2247282T3 PL 09705454 T PL09705454 T PL 09705454T PL 09705454 T PL09705454 T PL 09705454T PL 2247282 T3 PL2247282 T3 PL 2247282T3
Authority
PL
Poland
Prior art keywords
octreotide
sustained release
release formulation
glycolide polymers
linear polylactide
Prior art date
Application number
PL09705454T
Other languages
English (en)
Inventor
Holger Petersen
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39577789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2247282(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2247282T3 publication Critical patent/PL2247282T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
PL09705454T 2008-01-30 2009-01-29 Preparat o przedłużonym uwalnianiu zawierający oktreotyd oraz trzy liniowe kopolimery poli(laktyd-co-glikolid) PL2247282T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08150826 2008-01-30
EP09705454.8A EP2247282B1 (en) 2008-01-30 2009-01-29 Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
PCT/EP2009/051026 WO2009095450A1 (en) 2008-01-30 2009-01-29 Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

Publications (1)

Publication Number Publication Date
PL2247282T3 true PL2247282T3 (pl) 2015-03-31

Family

ID=39577789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09705454T PL2247282T3 (pl) 2008-01-30 2009-01-29 Preparat o przedłużonym uwalnianiu zawierający oktreotyd oraz trzy liniowe kopolimery poli(laktyd-co-glikolid)

Country Status (14)

Country Link
US (2) US20110003002A1 (pl)
EP (1) EP2247282B1 (pl)
JP (2) JP5791278B2 (pl)
KR (2) KR20100110848A (pl)
CN (2) CN101917969A (pl)
AU (1) AU2009209594A1 (pl)
BR (1) BRPI0907011A8 (pl)
CA (1) CA2713339C (pl)
ES (1) ES2522342T3 (pl)
MX (1) MX2010008365A (pl)
PL (1) PL2247282T3 (pl)
PT (1) PT2247282E (pl)
RU (1) RU2541104C2 (pl)
WO (1) WO2009095450A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526700B (zh) * 2011-12-31 2014-08-06 江苏奥赛康药业股份有限公司 一种注射用醋酸奥曲肽冻干组合物及其制备方法
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
CN106727358A (zh) * 2017-01-24 2017-05-31 广州帝奇医药技术有限公司 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
WO2022231930A1 (en) * 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2023016565A1 (zh) * 2021-08-13 2023-02-16 江西济民可信集团有限公司 一种微球悬液、微粒制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CA2316052C (en) 1989-07-07 2008-09-02 David Bodmer Sustained release formulations of water soluble peptides
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
DK1539101T3 (da) * 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
CN1713890A (zh) * 2002-11-06 2005-12-28 阿尔萨公司 控释储库制剂
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
WO2005009357A2 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
WO2007071395A1 (en) * 2005-12-22 2007-06-28 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Also Published As

Publication number Publication date
KR20100110848A (ko) 2010-10-13
JP2015107985A (ja) 2015-06-11
KR101921800B1 (ko) 2018-11-23
RU2010135629A (ru) 2012-03-10
KR20160052756A (ko) 2016-05-12
WO2009095450A1 (en) 2009-08-06
EP2247282A1 (en) 2010-11-10
CN104127367A (zh) 2014-11-05
US8999390B2 (en) 2015-04-07
JP2011510951A (ja) 2011-04-07
MX2010008365A (es) 2010-08-23
PT2247282E (pt) 2014-11-11
US20120226224A1 (en) 2012-09-06
BRPI0907011A8 (pt) 2015-09-29
CA2713339A1 (en) 2009-08-06
CN101917969A (zh) 2010-12-15
RU2541104C2 (ru) 2015-02-10
CA2713339C (en) 2017-01-17
BRPI0907011A2 (pt) 2015-07-07
AU2009209594A1 (en) 2009-08-06
ES2522342T3 (es) 2014-11-14
EP2247282B1 (en) 2014-08-20
US20110003002A1 (en) 2011-01-06
JP5791278B2 (ja) 2015-10-07

Similar Documents

Publication Publication Date Title
IL191842A0 (en) Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
IL213034A (en) Stored formulations containing octrautide and two linear polylactide-line-glycolide polymers
IL208591A0 (en) Nanoparticle formulations and uses thereof
BRPI0922989A2 (pt) Liberação sustentada de nutrientes in vivo
GEP20135845B (en) Orally-disintegrating solid formulation
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
IL210804A (en) Benzylidenehydrazides and their uses
ZA201005849B (en) Linear order release polymer
HUE059436T2 (hu) PSMA-kötõ szerek és alkalmazásaik
ZA201101896B (en) Frizzled-binding agents and uses thereof
ZA201003262B (en) Fast release solid formulation, preparation and use thereof
EP2233511A4 (en) NOVEL POLYMER PARTICLE AND USE THEREOF
EP2274043A4 (en) BIODEGRADABLE METAL-CHELATING POLYMERS AND VACCINES
EP2323671A4 (en) BIODEGRADABLE AABB POLY (DEPSIPEPTIDE) POLYMERS AND METHOD FOR THEIR USE
PL2086567T3 (pl) Formulacje o przedłużonym uwalnianiu zawierające polimery o bardzo niskim ciężarze cząsteczkowym
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
PL2247282T3 (pl) Preparat o przedłużonym uwalnianiu zawierający oktreotyd oraz trzy liniowe kopolimery poli(laktyd-co-glikolid)
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201003680B (en) Oral care methods and systems
ZA201103456B (en) Leukolectins and uses thereof
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
ZA201102518B (en) Modified release formulation and methods of use
GB0823497D0 (en) Immunogenic composition and use thereof
IL202722A0 (en) 4-imidazolines and their use as antidepressants
GB2460965B (en) Fibrillar albumin and uses thereof